Does VORASIDENIB Cause Malignant neoplasm progression? 25 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Malignant neoplasm progression have been filed in association with VORASIDENIB (VORANIGO). This represents 9.5% of all adverse event reports for VORASIDENIB.
25
Reports of Malignant neoplasm progression with VORASIDENIB
9.5%
of all VORASIDENIB reports
2
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From VORASIDENIB?
Of the 25 reports, 2 (8.0%) resulted in death, 3 (12.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VORASIDENIB. However, 25 reports have been filed with the FAERS database.
What Other Side Effects Does VORASIDENIB Cause?
Alanine aminotransferase increased (33)
Fatigue (27)
Aspartate aminotransferase increased (26)
Seizure (21)
Hepatic cytolysis (18)
Headache (17)
Hepatic enzyme increased (17)
Gamma-glutamyltransferase increased (16)
Nausea (16)
Hepatotoxicity (13)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which VORASIDENIB Alternatives Have Lower Malignant neoplasm progression Risk?
VORASIDENIB vs VORETIGENE NEPARVOVEC-RZYL
VORASIDENIB vs VORICONAZOLE
VORASIDENIB vs VORINOSTAT
VORASIDENIB vs VORTIOXETINE
VORASIDENIB vs VORTIOXETINE HYDROBROMIDE